MEDP Articles, Medpace Holdings Inc.

QIAGEN N.V. (NYSE: QGEN) recently lauded the new guidelines in the United States that recommend screening at-risk children of all ages for lat...

Charles River Laboratories' (NYSE: CRL) Research Models and Services (RMS) business continues to benefit from the Charles River Accelerator and...

Following three years of nonstop regulatory hassles, Illumina (NASDAQ: ILMN) finally gave up on GRAIL (NASDAQ: GRAL), leading to the successful com...

Abbott's (NYSE: ABT) diversified business portfolio is well-positioned to drive continued momentum in 2024. However, a challenging macroeconomi...

Zimmer Biomet (NYSE: ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence-...

Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. ...

Abbott (NYSE: ABT) announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are b...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year re...

Wall Street's popular adages are not matching this year. April is historically known for being favorable to investors. But this year, April end...

Medpace Hldgs (NASDAQ:MEDP) has outperformed the market over the past 5 years by 36.06% on an annualized basis producing an average annual return o...